| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(10)60399-6 |
| P698 | PubMed publication ID | 20417840 |
| P2093 | author name string | André J Scheen | |
| Régis P Radermecker | |||
| P2860 | cites work | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 |
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | Q34598940 | ||
| The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone | Q34608300 | ||
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial | Q43086322 | ||
| Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy | Q46173840 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | Q46804059 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study | Q94706600 | ||
| P433 | issue | 9724 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1410-1412 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Addition of incretin therapy to metformin in type 2 diabetes | |
| P478 | volume | 375 |
| Q38266290 | A review of gliptins for 2014. |
| Q37965612 | A review of gliptins in 2011. |
| Q41480632 | Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. |
| Q38902321 | DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects |
| Q33661003 | Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine. |
| Q37778379 | Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions |
| Q38082848 | Efficacy and safety of Jentadueto® (linagliptin plus metformin). |
| Q42914097 | Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus |
| Q84502134 | Gliptin versus a sulphonylurea as add-on to metformin |
| Q38152405 | Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials |
| Q38078436 | Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation |
| Q37933408 | Liraglutide: clinical pharmacology and considerations for therapy |
| Q51323275 | Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy. |
| Q37779779 | Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin |
| Q38455771 | Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes |
| Q38261573 | Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes |
| Q37982112 | Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment |
| Q38115636 | The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. |
| Q87392425 | Which incretin-based therapy for type 2 diabetes? |
Search more.